They found that for FDA approved GLP-1s for weight loss, liraglutide (Saxenda) and semaglutide (Wegovy), the percent of side effects reported was as follows: Nausea: 42.2% Diarrhea: 21.9% Vomiting: also 21.9% Constipation: 8.4% They report that although the incidence of side effects were similar among medications, semaglutide had the greatest risk of nausea, diarrhea, and vomiting, whereas liraglutide had the greatest risk of upper abdominal pain
Cell Stem Cell 23 , 516529.e5 (2018)
The usual dose is 1 mL, which means 1,000 mcg of B12 per shot
Microbial metabolism of dietary components to bioactive metabolites: Opportunities for new therapeutic interventions
The most commonly reported effects include: Mild water retention during the first 2 to 4 weeks Occasional headaches, particularly at treatment initiation Redness or irritation at the injection site Tingling or numbness in the extremities Short term fatigue or flushing after injection Ipamorelins selectivity provides a meaningful safety advantage
